Patents by Inventor Sharon McKenna

Sharon McKenna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9767146
    Abstract: Various embodiments of a method, apparatus and article of manufacture provide a decision point in a workflow system comprising a server and at least a first client work node. A decision point work node is provided at the server. A SQL expression which is associated with the decision point work node and the first client work node is generated. The server determines whether to route a work package to the first client work node based on the SQL expression.
    Type: Grant
    Filed: August 31, 2004
    Date of Patent: September 19, 2017
    Assignee: INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: Rupa Bhaghavan, Wayne Frederick Miller, Kenneth Carlin Nelson, Sharon McKenna Sanders, Fang-Yi Wang
  • Patent number: 9155761
    Abstract: The invention is based on the surprising finding that treatment with a chemotherapeutic agent such as 5-fluorouracil (5-FU) and an autophagy inducer effectively inhibit the continued growth of, and prevent the recovery following drug withdrawal, of cancer cells. In vivo, drug resistance from a failure to adequately engage in apoptotic programmed cell death leads to a recurrence of cancer and tumors can remain dormant for periods of time before re-emerging as drug resistant metastases. It has been hypothesized that autophagy (Type II cell death) may help cancer cells survive in response to growth limiting conditions, such as nutrient depletion, hypoxia, absence of growth factor, or presence of cytotoxic drug. LiCl is a known autophagy inducer and accelerates cell survival to autophagic programmed cell death.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: October 13, 2015
    Assignee: University of College Cork, National University of Ireland
    Inventors: Sharon McKenna, Gerald C. O'Sullivan, Tracey O'Donovan
  • Patent number: 8431587
    Abstract: The invention is based on the surprising finding that treatment with a chemotherapeutic agent such as 5-fluorouracil (5-FU) and an autophagy inducer effectively inhibit the continued growth of, and prevent the recovery following drug withdrawal, of cancer cells. In vivo, drug resistance from a failure to adequately engage in apoptotic programmed cell death leads to a recurrence of cancer and tumours can remain dormant for periods of time before re-emerging as drug resistant metastases. It has been hypothesised that autophagy (Type II cell death) may help cancer cells survive in response to growth limiting conditions, such as nutrient depletion, hypoxia, absence of growth factor, or presence of cytotoxic drug. LiCl is a known autophagy inducer and accelerates cell survival to autophagic programmed cell death.
    Type: Grant
    Filed: July 15, 2010
    Date of Patent: April 30, 2013
    Assignee: University College Cork, National University of Ireland, Cork
    Inventors: Sharon McKenna, Gerald C. O'Sullivan, Tracey O'Donovan
  • Patent number: 8056012
    Abstract: Devices, methods, and computer programs are disclosed for providing a graphical workflow programming environment for routing documents. First a workflow design platform is provided that comprises a process canvas for receiving at least one graphical workflow programming object. Next, a graphical representation of the graphical workflow programming object is provided where the graphical representation is adapted to be selected by an administrator of the graphical workflow programming environment and inserted into the process canvas, wherein the graphical workflow programming object comprises a graphical decision point that is adapted to route the documents based on contents of the documents.
    Type: Grant
    Filed: December 15, 2004
    Date of Patent: November 8, 2011
    Assignee: International Business Machines Corporation
    Inventors: Ying-Pong Chen, Gregory Scott Johnston, Wayne F. Miller, Sharon McKenna Sanders, Alan Tsu-I Yaung
  • Publication number: 20110014303
    Abstract: The invention is based on the surprising finding that treatment with a chemotherapeutic agent such as 5-fluorouracil (5-FU) and an autophagy inducer effectively inhibit the continued growth of, and prevent the recovery following drug withdrawal, of cancer cells. In vivo, drug resistance from a failure to adequately engage in apoptotic programmed cell death leads to a recurrence of cancer and tumours can remain dormant for periods of time before re-emerging as drug resistant metastases. It has been hypothesised that autophagy (Type II cell death) may help cancer cells survive in response to growth limiting conditions, such as nutrient depletion, hypoxia, absence of growth factor, or presence of cytotoxic drug. LiCl is a known autophagy inducer and accelerates cell survival to autophagic programmed cell death.
    Type: Application
    Filed: July 15, 2010
    Publication date: January 20, 2011
    Applicant: UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND, CORK
    Inventors: Sharon McKenna, Gerald C. O'Sullivan, Tracey O'Donovan